'Prac­ti­cal­ly im­pos­si­ble': On the dif­fi­cul­ties of in­tro­duc­ing new med­i­cines across all 27 EU mem­ber states

Time­ly and eq­ui­table ac­cess to new med­i­cines across all 27 EU mem­ber states has been near the top of every list for the Eu­ro­pean Com­mis­sion in de­scrib­ing what it wants to achieve with the over­haul of its 20-year-old phar­ma leg­is­la­tion.

The on­ly prob­lem is that bridg­ing that gap in ac­cess is go­ing to be a Her­culean task as cur­rent­ly, East­ern Eu­ro­pean coun­tries like Latvia, Lithua­nia and oth­ers on­ly see a small frac­tion of the new drugs that launch across oth­er, wealth­i­er coun­tries like Ger­many and Aus­tria.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN